[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-papillomavirus-related-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-papillomavirus-related-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100587259","interpersonal-communication-training-and-vaccination-workflow-training-alone-and-in-combination-to-improve-communication-and-recommendations-about-hpv-vaccination-in-pharmacies-impact-hpv-trial-100587259",false,"NCT06926062","Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","Implementing a Proactive Approach to Communicate and Teach About HPV Vaccination in Pharmacies: IMPACT HPV Study","Inclusion Criteria:\n\n* OBJECTIVE 1: Adults aged 18 years or older who live in the 50 United States (U.S.) states and Washington District of Columbia (D.C.) and are parents or guardians of children ages 9-17 are eligible to take the national survey (n ≤ 1,600, with anticipated enrollment of n = \\~1,500)\n* OBJECTIVE 2: Pharmacy staff at participating pharmacies (n ≤ 100)\n* OBJECTIVE 2: Adults aged 18 years or older whose children ages 9-17 received an HPV vaccine at one of the participating pharmacies in study year 2 (n ≤ 200)\n\nExclusion Criteria:\n\n* OBJECTIVE 1: Non-English speaking as the survey is only available for this project in English\n* OBJECTIVE 1: Parents whose index children have completed the HPV vaccine series\n* OBJECTIVE 2: Non-English speaking as the study funding only provided resources for surveys and interview materials to be available in English\n* OBJECTIVE 2: Parents whose index children have completed the HPV vaccine series",true,"ALL","18 Years",{"count":20,"type":21},1900,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial compares usual care to interpersonal communication training and vaccination workflow training, alone or in combination, for improving communication about and recommendations for human papillomavirus (HPV) and other vaccinations in pharmacies. Low HPV vaccination in the United States has placed unvaccinated children at risk of developing cancers as adults that could have been prevented. Pharmacies can be convenient for vaccination because they are open longer hours, have shorter wait times, can see patients without appointments and may cost less. However, many people are not aware that vaccination is available in pharmacies and some pharmacies lack the commitment from staff to vaccinate or may not have protocols in place for vaccination. Proactive communication approaches to recommending HPV vaccination have been shown to be effective in medical offices but have not been tested in the pharmacy setting. Interpersonal communication training incorporates the 5 A's (assess, advice, agree, assist and arrange) behavioral counseling framework to strongly recommend HPV and other vaccines and effectively answer any questions or concerns about vaccination. Vaccination workflow training establishes vaccination decision support strategies that pharmacies use to improve vaccination workflows. Interpersonal communication training and vaccination workflow training alone or in combination may improve communication and recommendations for HPV vaccination and increase HPV vaccination in pharmacies.",[27],"Human Papillomavirus-Related Carcinoma","RECRUITING","2026-07-29",{"date":31,"type":32},"2026-07-30","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2027-12-01",{"name":38,"class":39},"Fred Hutchinson Cancer Center","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100514990","phase-1-testing-rg1-vlp-vaccine-to-prevent-hpv-related-cancers-100514990","NCT05985681","Testing RG1-VLP Vaccine to Prevent HPV-related Cancers","A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer","Inclusion Criteria:\n\n* Women, age 18 - 60 years. Because no dosing or adverse event (AE) data is currently available for the use of RG1-VLP in humans, children and adolescents are excluded from this study\n* White blood cell (WBC) between 3000\u002Fmm\\^3 - institutional upper limit of normal\n* Hemoglobin (Hgb) between 10 g\u002Fdl - institutional upper limit of normal\n* Platelets \\>= 100,000\u002Fmm\\^3\n* Serum creatinine within institutional normal limits\n* Bilirubin =\\\u003C 2x institutional upper limit of normal\n* Alanine aminotransferase (ALT) =\\\u003C 2x institutional upper limit of normal\n* Aspartate aminotransferase (AST) =\\\u003C 2x institutional upper limit of normal\n* Human immunodeficiency virus (HIV)-1\u002FHIV-2 negative\n* Hepatitis B and hepatitis C negative\n* The effects of RG1-VLP vaccination on the developing human fetus at the proposed doses are unknown. For this reason, all women of childbearing potential will have a pregnancy test and all heterosexually active women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* The following persons are not considered to be able to bear children and are therefore eligible to participate without the use of concurrent birth control:\n\n  * Female with bilateral oophorectomy and\u002For hysterectomy\n  * Female with fallopian tubes cut, tied or sealed\n  * Female with sterilization implant (e.g. Adiana, Essure) placed \\> 3 months prior to randomization\n  * Female post-menopausal (\\> 1 year since last menses or prior laboratory follicle stimulating hormone \\[FSH\\] value per institutional range indicating post-menopausal)\n* Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 1\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of any of the following:\n\n  * Prior or current genital warts\n  * Treatment for anogenital intraepithelial neoplasia (cervical intraepithelial neoplasia \\[CIN\\], anal intraepithelial neoplasia \\[AIN\\], vaginal intraepithelial neoplasia \\[VAIN\\], vulvar intraepithelial neoplasia \\[VIN\\])\n  * Systemic cancer treatment within the prior year\n* History of anaphylaxis to vaccines\n* Any prior vaccination with Gardasil, Gardasil-9, or Cervarix or other HPV vaccine\n* Receipt of blood products within 3 months of enrollment, or continuing plasma donation\n* Participants receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the adjuvant or to RG1-VLP\n* Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or preclude protocol vaccination\n* Pregnant women or actively lactating women are excluded from this study because RG1-VLP is a vaccine with the potential for teratogenic or abortifacient effects\n* Planned receipt of any inactivated vaccine in the 2 weeks preceding and the 2 weeks following any trial vaccination\n* Planned receipt of any live attenuated vaccine in the 4 weeks preceding and the 4 weeks following any trial vaccination\n* Women with a history of bleeding disorders or use of anticoagulants (aspirin is acceptable)\n* Had prior medical diagnoses:\n\n  * Rheumatoid arthritis or other auto-immune disease\n  * Congenital or acquired immunodeficiency\n  * Collagen vascular disease\n* Following medical treatments:\n\n  * Current use of immunosuppressive drugs including corticosteroid use (inhaled or topical steroids are permitted)\n* Unrecovered major infections and\u002For surgical procedures","FEMALE","60 Years",{"count":51,"type":21},18,[53],"PHASE1","This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. Gardasil-9 is approved by the Federal Drug Administration to help protect against diseases caused by some types of HPV. Gardasil-9 also contains 9 different HPV proteins. Both vaccines contain alum to stimulate the immune system. The usual approach for the prevention of HPV-related cancers for patients who are at increased risk is to consider the currently approved HPV vaccine like Gardasil-9, as well as to be followed closely by their doctor to watch for the development of cancer via routine pap smears. This trial may allow researchers to find out whether the RG1-VLP vaccine can safely trigger an immune response against HPV in healthy women and if it is better or worse than the usual approach for the prevention of HPV-related cancers.",[27],"2026-06-23",{"date":58,"type":32},"2026-06-24",{"date":60,"type":32},"2026-01-27",{"date":62,"type":21},"2028-08-01",{"name":64,"class":65},"National Cancer Institute (NCI)","NIH",5,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":16,"sex":17,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100600957","a-vaccine-promotion-package-tweenvax-to-improve-adolescent-hpv-vaccination-tweenvax-trial-100600957","NCT07104240","A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial","TweenVax: A Comprehensive Practice-, Provider-, and Parent\u002FPatient-Level Intervention to Improve Adolescent HPV Vaccination","Inclusion Criteria:\n\n* PRACTICE-LEVEL: Must be community based primary care providers (pediatrics or family practice)\n* PRACTICE-LEVEL: Are willing to be part of the study\n* PRACTICE-LEVEL: Have sufficient patient population to support 51 adolescents aged 9-12 years over approximately a 9-month period\n* PRACTICE-LEVEL: Utilize an electronic medical records system and\u002For report to the state Immunization Information System (IIS)\n* CHILD\u002FADOLESCENT: Aged 9-12 years\n* CHILD\u002FADOLESCENT: Seeking care from an enrolled practice during the study period\n* CHILD\u002FADOLESCENT: Have not received any doses of HPV vaccine by the time of their first visit during the study period","9 Years",{"count":76,"type":21},1836,[24],"This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed by the age of 13. It has been estimated that only about 16% of adolescents were fully up to date with HPV vaccines by age 13. Strong and consistent provider recommendations have been shown to play an important role in the uptake of vaccines. In addition, education and information received by parents may improve the strength of recommendations by providers. The TweenVax intervention includes practice, provider, parent and patient level education to teach best practices, help with vaccine messaging, and give correct and easy to understand information to parents. Providing practice, provider and parent level access to TweenVax may be more effective than current vaccine promotion practices in improving HPV vaccination rates in adolescents.",[27],"2025-08-04",{"date":82,"type":32},"2025-08-05",{"date":84,"type":32},"2025-05-02",{"date":86,"type":21},"2028-03-06",{"name":88,"class":39},"Emory University",1]